- Distec will exclusively bring Howard Medical’s popular US mobile cart offering to the UK and Irish markets
- The mobile carts enable healthcare professionals to maximise investments, reduce total cost of ownership, increase efficiency and enhance patient care
The carts, manufactured by Howard Medical, enable healthcare professionals to not only maximise investments, but increase efficiency and enhance patient care. They are also equipped with a wide range of unparalleled features including intelligent ergonomics, on-demand steer assist technology, outstanding battery life and flexible storage, all designed to be completely customisable to work with any specialist department.
Howard Medical’s offering is already well established in the US and with Distec’s 26-years’ of experience in the UK health industry, they were the natural fit as the sole provider of the carts for a UK and Ireland expansion. The launch of the carts is especially timely as the NHS and healthcare providers look to move to an era of digital transformation after Health Secretary Matt Hancock pledged a £487m technology boost.
Distec already works with a range of global partners in order to deliver cutting-edge healthcare technology. Their products and solutions are all designed to complement each other, and the carts will be the perfect addition to their existing health tech portfolio, encompassing interactive solutions, high-performing medical grade computers, self-service stands and digital signage.
Noel Sheppard, Director of Distec said: “Partnering with Howard Medical enables Distec to offer a complete healthcare solution. Digital technology is transforming the healthcare industry and our solutions enable medical professionals to realise the benefits of technology to improve the quality of healthcare delivery.”
Wes Craddock, International Sales Manager at Howard Medical added: “Howard Medical has a proven track record of delivering innovative technology solutions for the healthcare industry in the US, and the strategic partnership with Distec means we can deliver the benefits realised in the US to the UK healthcare market’.